Mice lacking the iNKT cell subset, compared with wild-type mice, respond to CTLA-4 blockade with markedly increased cure rate and overall survival, indicating that iNKT cells might play a role in efficacy of cancer immunotherapy (132). The gene discussed is CTLA4; the disease is cancer.